scholarly journals Genetic and Environmental Factors for Type 1 Diabetes: Data from the province of Oristano, Sardinia, Italy

Diabetes Care ◽  
2001 ◽  
Vol 24 (10) ◽  
pp. 1846-1847 ◽  
Author(s):  
O. Frongia ◽  
C. Pascutto ◽  
G. M. Sechi ◽  
M. Soro ◽  
R. M. Angioi
F1000Research ◽  
2016 ◽  
Vol 5 ◽  
pp. 110 ◽  
Author(s):  
Gustaf Christoffersson ◽  
Teresa Rodriguez-Calvo ◽  
Matthias von Herrath

Type 1 diabetes is a multifactorial disease in which genetic and environmental factors play a key role. The triggering event is still obscure, and so are many of the immune events that follow. In this brief review, we discuss the possible role of potential environmental factors and which triggers are believed to have a role in the disease. In addition, as the disease evolves, beta cells are lost and this occurs in a very heterogeneous fashion. Our knowledge of how beta cell mass declines and our view of the disease’s pathogenesis are also debated. We highlight the major hallmarks of disease, among which are MHC-I (major histocompatibility complex class I) expression and insulitis. The dependence versus independence of antigen for the immune infiltrate is also discussed, as both the influence from bystander T cells and the formation of neo-epitopes through post-translational modifications are thought to influence the course of the disease. As human studies are proliferating, our understanding of the disease’s pathogenesis will increase exponentially. This article aims to shed light on some of the burning questions in type 1 diabetes research.


2015 ◽  
Vol 17 (8) ◽  
pp. 559-566 ◽  
Author(s):  
Emma Altobelli ◽  
Reimondo Petrocelli ◽  
Alberto Verrotti ◽  
Francesco Chiarelli ◽  
Ciro Marziliano

Science ◽  
2021 ◽  
Vol 373 (6554) ◽  
pp. 510-516
Author(s):  
Jeffrey A. Bluestone ◽  
Jane H. Buckner ◽  
Kevan C. Herold

Type 1 diabetes (T1D) is an autoimmune disease in which T cells attack and destroy the insulin-producing β cells in the pancreatic islets. Genetic and environmental factors increase T1D risk by compromising immune homeostasis. Although the discovery and use of insulin have transformed T1D treatment, insulin therapy does not change the underlying disease or fully prevent complications. Over the past two decades, research has identified multiple immune cell types and soluble factors that destroy insulin-producing β cells. These insights into disease pathogenesis have enabled the development of therapies to prevent and modify T1D. In this review, we highlight the key events that initiate and sustain pancreatic islet inflammation in T1D, the current state of the immunological therapies, and their advantages for the treatment of T1D.


2017 ◽  
Vol 08 (02) ◽  
Author(s):  
Basma Abdelmoez Ali ◽  
Mostafa Ahmed Elfoly ◽  
Eman Ramadan Ghazawy ◽  
Rania Rashad Bersom

Diabetes Care ◽  
2001 ◽  
Vol 24 (1) ◽  
pp. 181-182 ◽  
Author(s):  
M. Hummel ◽  
A.-G. Ziegler

2012 ◽  
Vol 2 ◽  
pp. 125-131 ◽  
Author(s):  
Anne-Louise Ponsonby ◽  
Angela Pezic ◽  
Fergus J. Cameron ◽  
Christine Rodda ◽  
Justine A. Ellis ◽  
...  

Sign in / Sign up

Export Citation Format

Share Document